

APR. 30. 2004 4:01PM

OBLON SPIVAK

NO. 030 P. 8

Docket No. 2194-0042-23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gwyn A. CUTSFORTH, et al.

SERIAL NO: NEW APPLICATION

FILED: HEREWITH

FOR: COAGULATION ASSAY REAGENTS CONTAINING LANTHANIDES AND A PROTEIN C ASSAY USING SUCH A LANTHANIDE-CONTAINING REAGENT

INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicants wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/98)

J. Derek Mason, Ph.D.

Attorney of Record

Registration No. 35,270

I:\atty\DJM\August 2001\21940042.idscvr.wpd

APR. 30. 2004 4:02PM

OBLON SPIVAK

NO. 030 P. 9

SHEET 1 OF 3

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 2194-0042-23		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Gwyn A. CUTSFORTH, et al.			
				FILING DATE HEREWITH		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	A. BROEKMANS, et al., "Congenital Protein C Deficiency and Venous Thromboembolism, A Study of Three Dutch Families", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 309, No. 6, pp. 340-344, 1983.					
	AX	J. GRIFFIN, et al., "Protein C, an Antithrombotic Protein, Is Reduced in Hospitalized Patients with Intravascular Coagulation", BLOOD, Vol. 60, No. 1 (July), pp. 261-264, 1982.					
	AY	R. MARLAR, et al., "Serial Studies of Protein C and Its Plasma Inhibitor in Patients with Disseminated Intravascular Coagulation", BLOOD, Vol. 66, No. 1 (July), pp. 59-63, 1985.					
	AZ	"Protein C in the Treatment of coagulopathy in meningococcal disease", THE LANCET, Vol. 347, page 1767, June 1996.					
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

APR. 30. 2004 4:02PM

OBLON SPIVAK

NO. 030 P. 10

SHEET 2 OF 3

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 2194-0042-23		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Gwyn A. CUTSFORTH, et al.			
				FILING DATE HEREWITH		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
AAA	O. P. SMITH, et al., "Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans", THE LANCET, Vol. 350, pp. 1590-1593, November 1997.						
AAB	R. FAVIER, et al., "Simultaneous administration of antithrombin III and protein C concentrates for the treatment of a devastating coagulopathy in a child", HEMATOL. CELL THER., Vol. 40, pp. 67-70, 1998.						
AAC	J. PARKINSON, et al., "Stable Expression of a Secretable Deletion Mutant of Recombinant Human Thrombomodulin in Mammalian Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 21, pp. 12602-12610, July 1990.						
AAD	B. GERLITZ, et al., "Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine ⁴⁶⁹ ", BIOCHEM. J., Vol. 295, pp. 131-140, 1993.						
AAE	D. T. BERG, et al., "High-Level Expression of Secreted Protein s from Cells Adapted to Serum-Free Suspension Culture", BIOTECHNIQUES, Vol. 14, No. 6, pp. 972-978, 1993.						
AAF	J. PARKINSON, et al., "STRUCTURE-FUNCTION STUDIES OF THE EPIDERMAL GROWTH FACTOR DOMAINS OF HUMAN THROMBOMODULIN", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 185, No. 2, pp. 567-576, 1992.						
AAG	C. E. WHITE, et al., "Large-scale expression, purification and characterization of small fragments of thrombomodulin: the roles of the sixth domain and of methionine 386", PROTEIN ENGINEERING, Vol. 8, No. 11, pp. 1177-1187, 1995.						
AAH	D. E. JACKSON, et al., "Purification and characterization of two forms of soluble thrombomodulin from human urine", EUR. J. BIOCHEM., Vol. 221, pp. 1079-1087, 1994.						
AAI	S. M. RICHARDS, et al., "Quantitative and Functional Assays compared for Determination of Zymogen and Activated Human Protein C", CLIN. CHEM. Vol. 36, No. 11, pp. 1892-1896, 1990.						
AAJ	L. BAJZAR, et al., "Both Cellular And Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating The Activation of Thrombin-activable Fibrinolysis Inhibitor", J. BIOL. CHEM., Vol. 273, No. 5, 1998. ABSTRACT ONLY						
AAK	M. F. HOCKIN, et al., "Inactivation on human umbilical vein endothelial cells", ARTERIOSCLER., THROMB., VASC. BIOL., Vol. 17, No. 11, 1997. ABSTRACT ONLY						
AAL	A. J. GALE, et al., "Nonenzymic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va", PROTEIN SCIENCE, Vol. 6, No. 1, 1997. ABSTRACT ONLY						
AAM	S. YU, et al., "Construction, Expression, and Properties of a Recombinant chimeric Human Protein C with Replacement of Its Growth Factor-like Domains by those of Human Coagulation Factor IX", BIOCHEMISTRY, Vol. 33, No. 3, 1994. ABSTRACT ONLY						
AAN	C. L. ORTHNER, et al., "A sensitive and facile assay for the measurement of activated protein C activity levels in vivo", THROMB. HAEMOSTASIS, Vol. 69, No. 5, 1993. ABSTRACT ONLY						
AAO	K. G. MANN, et al., "Active site-specific immunoassays", BLOOD, Vol. 76, No. 4, 1990. ABSTRACT ONLY						
AAP	K. F. STOCKER, et al., "Snake protein C activator, methods of preparation and use thereof", US Patent. ABSTRACT ONLY						
AAQ	S. NAKAMURA, et al., "Assay methods for protein C (and protein S)", RINSHO BYORI, RINJI ZOKAN, Vol. 70, 1987. ABSTRACT ONLY						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

APR. 30. 2004 4:02PM

OBLON SPIVAK

NO. 030 P. 11

SHEET 3 OF 3

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 2194-0042-23		SERIAL NO. NEW APPLICATION	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Gwyn A. CUTSFORTH, et al.			
				FILING DATE HEREWITH		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	BB A	G. A. SOFF, et al., "Protein C levels in nephrotic syndrome: use of a new enzyme-linked immunoadsorbent assay for protein C antigen", AM. J. HEMATOL., Vol. 22, No. 1, 1986. ABSTRACT ONLY					
	BB B	R. M. BERTINA, et al., "The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency", THROB. HAEMOSTASIS, Vol. 51, No. 1, 1984. ABSTRACT ONLY					
	BB C						
	BB D						
	BB E						
	BB F						
	BB G						
	BB H						
	BB I						
	BB J						
	BB K						
	BB L						
	BB M						
	BB N						
	BB O						
	BB P						
	BB Q						
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

APR. 30. 2004 4:02PM

OBLON SPIVAK

NO. 030 P. 12

Dept.: CHEMICAL

OSMM&N File No. 2194-0042-23

By: IDM:ekd

Serial No. NEW APPLICATION

In the matter of the Application of: Gwyn A. CUTSFORTH, et al.

For: COAGULATION ASSAY REAGENTS CONTAINING LANTHANIDES
AND A PROTEIN C ASSAY USING SUCH A LANTHANIDE-
CONTAINING REAGENT

The following has been received in the U.S. Patent Office on the date stamped herein:

- ☒ 26 pp. Specification & \$4 Claims/Drawings 9 Sheets
 - and 2 pages Application Data Sheet
 - ☐ Combined Declaration, Petition & Power of Attorney (pages,)
 - ☐ List of Inventor Names and Addresses
 - ☒ Utility Patent Application Transmittal
 - ☐ Request for Priority
 - ☒ Check for \$2,632.00
 - ☒ Fee Transmittal Form
 - ☐ Assignment/PTO 1595 pages:
 - ☐ Letter to Official Draftsman
 - ☐ Letter Requesting Approval of Drawing Changes
 - ☐ Drawings sheets ☐ Formal
 - ☐ PTO Cover Letter
 - ☐ Amendment
 - ☒ Information Disclosure Statement
 - ☒ Cited References (23)
 - ☐ Search Report
 - ☐ Statement of Relevancy
 - ☐ IDS/Related/List of Related Cases
 - ☐ Response to Restriction Requirement
 - ☐ Rule 132 Declaration
 - ☐ Request for Extension of Time under 37 C.F.R. §1.136 ()
 - ☐ Notice of Appeal
 - ☐ Appeal Brief
 - ☐ Reply Brief
 - ☐ Issue Fee Transmittal
 - ☒ White Advance Serial Number Card
 - ☐
- ☐ CPA
☐ Priority Doc
☒ Dep. Acct. Order Form
- ☐ PTO-1449
- ☐ Cited Pending Applications ()
- ☐ Election Response

Due Date: August 27, 2001

APR. 30. 2004 4:03PM

OBLON SPIVAK

NO. 030 P. 13

Docket No. 2194-0042-23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gwyn A. CUTSFORTH, et al.

SERIAL NO: 09/938,728

GAU: 1651

FILED: August 27, 2001

EXAMINER:

FOR: COAGULATION ASSAY REAGENTS CONTAINING LANTHANIDES AND A PROTEIN C ASSAY USING SUCH A LANTHANIDE-CONTAINING REAGENT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☒ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment form is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

J. Derek Mason

Registration No. 35,270

APR. 30. 2004 4:03PM

OBLON SPIVAK

NO. 030 P. 14

SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 2194-0042-23		SERIAL NO. 09/938,728	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Gwyn A. CUTSFORTH, et al.			
				FILING DATE August 27, 2001		GROUP 1651	
				U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	Written Opinion, PCT/US02/03357, International filing date: February 7, 2002, 4 pages.					
	AX						
	AY						
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Dept.: CHEMICALBy: JDM//safOSMM&N File No. 2194-0042-23Serial No. 09/938,728In the matter of the Application of: Gwyn A. CUTSFORTH, et al.For: COAGULATION ASSAY REAGENTS CONTAINING LANTHANIDES
AND A PROTEIN C ASSAY USING SUCH A LANTHANIDE-
CONTAINING REAGENTDue Date: August 7, 2003

The following has been received in the U.S. Patent Office on the date stamped hereon

- Dep. Acct. Order Form
- PTO Cover Letter
- Amendment (19 pp.)
- Information Disclosure Statement
- PTO-1449
- Written Opinion (3 pp.)

